All filters
Abstracts
An assay to measure drug tolerance of M. tuberculosis in the caseous center of pulmonary lesions
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Levofloxacin target attainment analysis in MDR-TB patients: time is ripe for proactive TDM
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Population Pharmacokinetics of Linezolid in TB Patients: Dosing Regimens Simulation and Target Attainment Analysis
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
PK-PD of isoniazid given at different doses among patients with MDR-TB with INH resistance mediated by inhA mutations: modeling results from ACTG A5312.
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
The OptiRIF study: pharmacokinetics of high-dose rifampicin in children
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Ethionamide population pharmacokinetic model and Monte Carlo Simulation in patients with multidrug-resistant tuberculosis
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Increased bactericidal activity but dose-limiting tolerability at 50 mg/kg rifampicin
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Pharmacogenetics and pharmacokinetics of first-line anti-tuberculosis drugs in the HIRIF trial
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Pharmacokinetics and Early Bactericidal Activity of Meropenem (with Amoxicillin/Clavulanate), With and Without Rifampicin, for Drug-Susceptible TB
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Co-administration of pretomanid with rifampin or rifabutin among patients with pulmonary TB: interim PK results from “Assessing Pretomanid for Tuberculosis” (APT) trial
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with drug-resistant TB
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Evaluating hepatotoxicity of bedaquiline treatment in multi-drug resistant tuberculosis patients
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Videos
Managing Complex Patients - US | Charles Flexner
Presented at:
Managing Complex HIV Patients 2020- US Edition
Videos
Managing Complex Patients - US | Monica Gandhi
Presented at:
Managing Complex HIV Patients 2020- US Edition
Videos
Managing Complex Patients - US | Sharon Walmsley
Presented at:
Managing Complex HIV Patients 2020- US Edition
Videos
Managing Complex Patients - US | Daniel Kuritzkes
Presented at:
Managing Complex HIV Patients 2020- US Edition
Videos
Managing Complex Patients - US | Michael Kozal
Presented at:
Managing Complex HIV Patients 2020- US Edition
Abstracts
An assessment of the effects of dolutegravir on gene expression and levonorgestrel clearance in human hepatocytes in vitro
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Cobicistat (COBI)-boosted Protease Inhibitors (PIs) plasma and intracellular (IC) pharmacokinetics (PK) in nicotine users
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Glecaprevir/pibrentasvir pharmacokinetics in HCV/HIV patients co-administered with antiretroviral drugs
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
The valproic acid – dolutegravir drug-drug interaction is based on displacement of protein binding and unlikely to be clinically relevant
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Valproic acid co-administration is not associated with lower non-dolutegravir antiretrovirals’ exposures
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019